Zydus Lifesciences shares in focus on completing acquisition of Assertio Holdings; key details

According to a regulatory filing, the cash tender offer for acquiring the NASDAQ-listed entity was completed at a purchase price of $23.50 per share of common stock of Assertio, without interest, less deduction for any required withholding taxes.

“As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on June 15, 2026, 4,286,488 shares of common stock were validly tendered and not withdrawn, representing approximately 66.32% of the total number of Assertio’s issued and outstanding shares of common stock,” Zydus Lifesciences said.

The company intended to complete the acquisition on June 16, 2026, through a merger of the purchaser, Zara Merger Sub, with and into Assertio, with the latter continuing as the surviving corporation.

Under this, all shares of common stock not tendered into the offer will be cancelled and converted into the right to receive cash equal to the $23.50 offer price per common share, without interest, less deduction for any required withholding taxes.

After the completion of the merger, Assertio will become a wholly owned subsidiary of Zydus Lifesciences, and the common stock of Assertio will no longer be listed or traded on the Nasdaq Global Market.

Zydus Lifesciences stock performance

Shares of Zydus Lifesciences closed 0.86% lower at ₹1,078.70 per unit on the National Stock Exchange (NSE) on Tuesday. However, the announcement was made after the market closed.

The scrip has fallen more than 2% in the past week but gained 7% over the month. On a year-to-date basis, it has risen 18%.

Zydus Lifesciences has a total market capitalisation of ₹1.09 lakh crore as of June 16, 2026, according to data on the NSE.